Top Story

Racial, treatment-related factors may influence bevacizumab efficacy in advanced cervical cancer

Racial, treatment-related factors may influence bevacizumab efficacy in advanced cervical cancer
February 7, 2016

Use of Moore criteria may identify patients with advanced cervical cancer who may not benefit from treatment with bevacizumab, according to results of a study conducted by the Gynecologic Oncology Group.

Further, patients with moderate- or high-risk disease appeared to derive the greatest benefit from treatment with bevacizumab (Avastin, Genentech/Roche).

Children’s Research Institute at Children’s Mercy appoints chief scientific officer

February 6, 2016
Tom Curran, PhD, FRS, has been hired as chief scientific officer and executive director of Children’s Research Institute at Children’s Mercy Kansas City.The…
Meeting News Coverage

Oncologists, PCPs disagree on who should provide cancer survivorship care

February 5, 2016
Oncologists and primary care physicians within the same integrated health system disagreed on who should ultimately manage care for survivors of cancer, according to…

ABIM continues to engage physicians on MOC updates

February 5, 2016
The ABIM has announced several new efforts aimed at including internists and subspecialists in the process of improving Maintenance of Certification assessments…
In the Journals

Artificial white light as effective as daylight photodynamic therapy for actinic keratosis

February 5, 2016
Artificial white light photodynamic therapy was as effective and tolerated as daylight photodynamic therapy in men with actinic keratosis, according to study results…
More News Headlines »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Meeting News CoverageVideo

VIDEO: Expert recaps three trials in gastric, esophageal cancer

January 26, 2016
More »

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Current Issues
View the Current Issue
HemOnc Today